The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | A retrospective study assessing ven-aza versus aza alone for treating AML in first relapse
Sylvain Garciaz, MD, Paoli-Calmettes Institute, Marseille, France, discusses a retrospective study comparing venetoclax (ven) plus azacitidine (aza) to azacitidine monotherapy in patients with acute myeloid leukemia (AML) in first relapse or refractory to intensive chemotherapy. The combination therapy resulted in an overall response rate (ORR) of 55% and a median survival of one year, compared to eight months for azacitidine alone. Multivariate analysis highlighted the factors predicting poorer overall survival (OS). This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
